Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Ilmarinen Mutual Pension Insurance Co boosted its stake in Amgen by a hefty 27.4% in Q4, acquiring 15,500 more shares.

Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits ...

Danish identical twins Rasmus and Nicolai Højgaard will make history as the first-ever set of twins to compete in the Masters ...

The pharmaceutical and healthcare sectors were previously viewed as a relative safe haven from the tariff-induced market turmoil. The Health Care Select Sector SPDR exchange-traded fund XLV fell 7.8% ...

Pfizer, Amgen, and Johnson & Johnson were among other pharma stocks that dropped at the US market open on April 9 amid ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average.

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $330.00. The ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $330 from $328 and keeps an Equal Weight rating on the ...

The US giants which supply vital new medicines to UK patients face disruption from Donald Trump’s trade barriers, experts ...